Home / Health / Diabetes Drug Mazdutide Now Covered by China's National Insurance
Diabetes Drug Mazdutide Now Covered by China's National Insurance
18 Nov
Summary
- Mazdutide added to national insurance for type 2 diabetes in adults.
- Zurletrectinib cancer drug also included in national insurance list.
- Both drugs will be covered starting January 1, 2027.
Innovent Biologics' dual-target drug mazdutide, marketed as Xinermei, has been included in China's updated national medical insurance drug list. This significant development targets adults diagnosed with type 2 diabetes, aiming to enhance treatment affordability and accessibility.
The drug, which activates GLP-1 and glucagon receptors to manage blood sugar and body weight, received regulatory approval in June 2025 for weight management and subsequently for type 2 diabetes in September 2025. Its new insurance coverage specifically applies to the diabetes indication.
China unveiled the updated list at a conference in Suzhou, Jiangsu province. The changes, effective January 1, 2027, also extend to six other Innovent medicines, bringing the total number of its drugs covered by national insurance to 17.
Additionally, InnoCare Pharma's domestically developed cancer drug zurletrectinib, known as Yinuoxin, has also been added to the national insurance list. This targeted therapy treats solid tumors with NTRK gene fusions in adults and adolescents aged 12 and above.
Zurletrectinib, approved in December 2025, is China's first domestically developed next-generation TRK inhibitor. Its inclusion is anticipated to improve access to crucial targeted treatments for patients with rare genetic alterations across various cancer types.